Cat No. 46-F92

CI-994

10 mg



For research purposes only

CI-994 is a histone deacetylase (HDAC) inhibitor that induces hyperacetylation in living cells. CI-994 mediates G_1 cell cycle arrest, inhibits proliferation and induces apoptosis *in vitro* and *in vivo*. CI-994 has also been shown to inhibit the growth of two non-small cell lung cancer (NSCLC) cell lines. CI-994 originally was developed as an anticonvulsant agent and later was reported to have antitumor activity.

TECHNICAL INFORMATION



STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 66 mg/ml. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

REFERENCES

Other Names: Acetyldinaline, Goe 5549, Gö 5549. PD 123654, Tacedinaline

Chemical Formula: C₁₅H₁₅N₃O₂

CAS Number: 112522-64-2

Molecular Weight: 269.30

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

- Kraker et al. (2003) Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther. 2(4):401-8.
- Graziano et al. (2001) Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI-994 (Acetyldinaline)(*). J Biomed Biotechnol. 1 (2):52-61.
- 3. Loprevite et al. (2005) In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 15(1):29-48.
- Hubeek et al. (2008) CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncol Rep. 19(6):1517-23.

